Vivalis raises its 2009 commercial targets.

Vivalis announced the signature of a new research agreement with a company whose name remains undisclosed for the production of monoclonal antibodies on its EB66 cell line platform. Since 1 Jan 2009, Vivalis has signed seven new commercial licenses, already outperforming the full-year commercial target announced 13 Jan 2009. Licence agreements signed since the start of 2009 have included: 3 commercial licenses with Innate Pharma (the first commercial licence in the field of therapeutic antibodies), OETC [a joint venture between Emergent Biosciences (USA) and the University of Oxford], and Fort Dodge (a subsidiary of the US company Wyeth); 4 research licenses with Boerhringer Ingelheim …